LDS/Medical Tests/Alprazolam, Urine

Alprazolam, Urine

Alprazolam belongs to the class of drugs known as Benzodiazepines. The Benzodiazepines are a class of medications (drugs) that can produce the following effects: sedation, anxiety relief, and nausea relief. They are one of the most widely prescribed drug classes in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS-depressants. Alprazolam is an intermediate acting triazolobenzodiazepine and is primarily used to treat anxiety and depression associated with anxiety symptoms. It is considered very potent and its potency is about 20 times that of diazepam.

Following an oral dose it is well absorbed with a bioavailability of about 90% in both conventional and extended release tablets. Approximately 80% of serum alprazolam is bound to albumin. Alprazolam is metabolized to alpha-hydroxyalprazolam and 4-hydroxyalprazolam in the liver by the cytochrome type CYP3A4. Both of these metabolites are less active than alprazolam and are typically detected in plasma at concentrations 1/2 is 11-12.5 hours for standard alprazolam and 11-16 hours for extended release preparations. The half-life is extended in Asians, geriatric and obese patients and those with severe liver disease.  Alprazolam crosses the placenta and is present in breast milk.

Alprazolam is the most commonly prescribed and abused benzodiazepine in the United States. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine abusers. Benzodiazepines are only legally available through prescription. Alprazolam and diazepam are two of the most frequently encountered benzodiazepines on the illicit market today.

Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by various analytical methods such as Gas Chromatography/Mass spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), and Immunoassay (IA). Benzodiazepines can elicit the following effects: amnesia, hostility, irritability, and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death.

  • Therapeutic monitoring in serum
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from a screening immunoassay (IA) type test indicates only the presence of a benzodiazepine and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as Gas Chromatography, Liquid Chromatography/Mass Spectroscopy or Gas Chromatography/MS.

Therapeutic concentration: 5-50 ng/mL
Toxic concentration: 100 - 400 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as immunoassay, or a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay, Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS). The main method of quantification is via LC/MS. This particular method of analysis is used to not only detect the parent drug compound, alprazolam, but also the major metabolites of alprazolam. These active metabolites should be quantitated to assess the overall effects of alprazolam. Alprazolam, as well as, all benzodiazepines, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, if desired, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis, since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 days
  • Refrigeration: 7 days
  • Frozen: 14 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19 may be tested for drug safety and efficacy before prescribing. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Barry Levine (Ed.). AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9 ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC (ed.). Disposition of Tox Drugs and Chemicals in Man, Sixth Edition, Biomedical Publications, Foster City, CA (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.